- Clinical Study
- Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
-
Hwa Young Ahn, Jae Eun Chae, Hyemi Moon, Junghyun Noh, Young Joo Park, Sin Gon Kim
-
Endocrinol Metab. 2020;35(4):811-819. Published online November 20, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.709
-
-
4,101
View
-
155
Download
-
8
Citations
-
 Abstract
 PDF Supplementary Material PubReader  ePub  Crossref - TDM
- Background
Thyroid cancer is becoming increasingly common worldwide, but little is known about the epidemiology of medullary thyroid carcinoma (MTC). This study investigated the current status of the incidence and treatment of MTC using Korean National Health Insurance Service (NHIS) data for the entire Korean population from 2004 to 2016.
Methods
This study included 1,790 MTC patients identified from the NHIS database.
Results
The age-standardized incidence rate showed a slightly decreasing or stationary trend during the period, from 0.25 per 100,000 persons in 2004 to 0.19 in 2016. The average proportion of MTC among all thyroid cancers was 0.5%. For initial surgical treatment, 65.4% of patients underwent total thyroidectomy. After surgery, external-beam radiation therapy (EBRT) was performed in 10% of patients, a proportion that increased from 6.7% in 2004 to 11.0% in 2016. Reoperations were performed in 2.7% of patients (n=49) at a median of 1.9 years of follow-up (interquartile range, 1.2 to 3.4). Since November 2015, 25 (1.4%) patients with MTC were prescribed vandetanib by December 2016.
Conclusion
The incidence of MTC decreased slightly with time, and the proportion of patients who underwent total thyroidectomy was about 65%. EBRT, reoperation, and tyrosine kinase inhibitor therapy are additional treatments after initial surgery for advanced MTC in Korea.
-
Citations
Citations to this article as recorded by  - Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef - Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma
Chan Kwon Jung, Shipra Agarwal, Jen-Fan Hang, Dong-Jun Lim, Andrey Bychkov, Ozgur Mete
Endocrine Pathology.2023; 34(1): 1. CrossRef - Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study
Xin Wu, Binglu Li, Chaoji Zheng
Technology in Cancer Research & Treatment.2022; 21: 153303382210784. CrossRef - Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research
Dae-Sung Kyoung, Hun-Sung Kim
Journal of Lipid and Atherosclerosis.2022; 11(2): 103. CrossRef - Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines
Daqi Zhang, Carla Colombo, Hui Sun, Hoon Yub Kim, Antonella Pino, Simone De Leo, Giacomo Gazzano, Luca Persani, Gianlorenzo Dionigi, Laura Fugazzola
Frontiers in Endocrinology.2022;[Epub] CrossRef - Total thyroidectomy vs thyroid lobectomy for localized medullary thyroid cancer in adults: A propensity-matched survival analysis
Weili Liang, Jinyuan Shi, Hui Zhang, Guixu Lv, Tiantian Wang, Yong Wang, Bin Lv, Luchuan Li, Qingdong Zeng, Lei Sheng
Surgery.2022; 172(5): 1385. CrossRef - Constitutive Cytomorphologic Features of Medullary Thyroid Carcinoma Using Different Staining Methods
Chih-Yi Liu, Chien-Chin Chen, Andrey Bychkov, Shipra Agarwal, Yun Zhu, Jen-Fan Hang, Chiung-Ru Lai, Hee Young Na, So Yeon Park, Weiwei Li, Zhiyan Liu, Deepali Jain, Ayana Suzuki, Mitsuyoshi Hirokawa, Noel Chia, Min En Nga, Tikamporn Jitpasutham, Somboon K
Diagnostics.2021; 11(8): 1396. CrossRef - Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer
Jinyoung Kim, Jun Park, Hyunju Park, Min Sun Choi, Hye Won Jang, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung
Cancers.2021; 13(22): 5842. CrossRef
|
KES
